Home/Filings/4/0001209191-19-004609
4//SEC Filing

Tsai Larry 4

Accession 0001209191-19-004609

CIK 0001373707other

Filed

Jan 17, 7:00 PM ET

Accepted

Jan 18, 6:05 PM ET

Size

12.3 KB

Accession

0001209191-19-004609

Insider Transaction Report

Form 4
Period: 2019-01-17
Tsai Larry
Chief Medical Officer
Transactions
  • Award

    Common Stock

    2019-01-06+3,33731,503 total
  • Award

    Common Stock

    2018-05-14+2,05833,561 total
  • Award

    Restricted Stock Units

    2019-01-17+40,00040,000 total
    Common Stock (40,000 underlying)
  • Award

    Restricted Stock Units

    2019-01-17+140,000140,000 total
    Common Stock (140,000 underlying)
Footnotes (5)
  • [F1]On January 6, 2016, the Reporting person was granted 8,000 restricted stock units ("RSUs")( the "2016 RSU grant") that were previously reported on Table II Of Form 4, which form was filed with the Securities and Exchange Commission on January 4, 2018. Of the 2016 RSU grant, an aggregate of 5,333 shares vested on January 6, 2018 and January 6, 2019 of which an aggregate of 1,996 shares were withheld by the Issuer to satisfy the reporting person's tax withholding obligations in connection with the delivery of the conversion of the RSUs into common stock on such vesting dates. The total number of shares beneficially owned by the reporting person includes the aggregate 3,337 RSUs converted into shares of common stock of the Issuer on each of the January 2018 and January 2019 vesting dates.
  • [F2]The amount of securities beneficially owned by the reporting person following the transaction reported on this Form 4 reflects the purchase by the reporting person of 2,058 shares of common stock on May 14, 2018 pursuant to the issuer's 2014 Employee Stock Purchase Plan.
  • [F3]Each restricted stock unit represents a contingent right to receive one share of common stock of Tetraphase Pharmaceuticals, Inc. for no consideration.
  • [F4]These restricted stock units shall be earned upon achievement of certain performance conditions and, if earned, shall vest on various dates beginning no earlier than March 1, 2020 and ending no later than March 1, 2022.
  • [F5]The restricted stock units vest in three equal installments on each of January 17, 2020, January 17, 2021 and January 17, 2022.

Issuer

TETRAPHASE PHARMACEUTICALS INC

CIK 0001373707

Entity typeother

Related Parties

1
  • filerCIK 0001725973

Filing Metadata

Form type
4
Filed
Jan 17, 7:00 PM ET
Accepted
Jan 18, 6:05 PM ET
Size
12.3 KB